While this case suggests that golimumab may rarely contribute to paradoxical IBD, it underscores the importance of evaluating anti-TNF agents individually, as previous reports have implicated etanercept more commonly than infliximab or adalimumab. The gene discussed is TNF; the disease is inflammatory bowel disease.